(Q41442058)

English

Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab

scientific article published on 9 March 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

1 reference

based on heuristic

inferred from title

Hepatitis B virus

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Yasuhito Tanaka

3

object named as

Yasuhito Tanaka

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

author name string

Hideki Ifuku

1

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Shigeru Kusumoto

2

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Haruhito Totani

4

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Masaya Okada

6

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Shuko Murakami

7

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Masashi Mizokami

8

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Ryuzo Ueda

9

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Shinsuke Iida

10

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

publication date

9 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Hepatology Research

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

1363-1367

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Antibody therapy for Adult T-cell leukemia-lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Immunopathogenesis of lymphoma: focus on CCR4.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Regulatory T-cell function of adult T-cell leukemia/lymphoma cells

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Immunobiology of hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12513

21 January 2018

Identifiers

10.1111/HEPR.12513

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41442058&oldid=2097762162"